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Abstract
Rheumatic fever (RF) is an autoimmune disease which affects more than 20 million children in developing countries. It is
triggered by Streptococcus pyogenes throat infection in untreated susceptible individuals. Carditis, the most serious
manifestation of the disease, leads to severe and permanent valvular lesions, causing chronic rheumatic heart disease
(RHD). We have been studying the mechanisms leading to pathological autoimmunity in RF/RHD for the last 15 years. Our
studies allowed us a better understanding of the cellular and molecular pathogenesis of RHD, paving the way for the
development of a safe vaccine for a post-infection autoimmune disease. We have focused on the search for protective Tand
B cell epitopes by testing 620 human blood samples against overlapping peptides spanning 99 residues of the C-terminal
portion of the M protein, differing by one amino acid residue. We identiﬁed Tand B cell epitopes with 22 and 25 amino acid
residues, respectively. Although these epitopes were from different regions of the C-terminal portion of the M protein, they
showed an identical core of 16 amino acid residues. Antibodies against the B cell epitope inhibited bacterial
invasion/adhesion in vitro. Our results strongly indicated that the selected T and B cell epitopes could potentially be
protective against S. pyogenes.
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Introduction
Rheumatic fever (RF) is a post-infectious auto-
immune disease which affects over 20 million children
worldwide, most of which are from developing
countries. This disease affects 3–4% of untreated
susceptible individuals infected by Streptococcus
pyogenes. Carditis is the most serious manifestation
of the disease, leading to severe and permanent
valvular lesions, which result in chronic rheumatic
heart disease (RHD).
RHD continues to be a major public health problem
in developing countries, leading to 233,000 deaths/
year (Carapetis et al. 2005a,b). The incidence of RHD
in the world is at least 15.6 million cases and the
highest documented prevalence of the disease among
children from developing countries is 5.7 per 1000 in
sub-Saharan Africa (Carapetis et al. 2005a,b).
Epidemiological data from many developing countries
are still of poor quality, and the numbers of RHD
cases are surely higher than those known. In Brazil,
although the incidence of acute rheumatic fever
(ARF) has decreased by 75% in the last 10 years, it
is still high, reaching 5000 new cases/year (data from
the Brazilian Health Ministry).
The highest incidence of ARF described is among
the aboriginal communities of Northern of Australia
(245-351/100,000 per year) and New Zealand
(80–100/100,000 per year) with an estimated 60%
of cases leading to RHD (Carapetis et al. 2005a,b).
In addition to RF and RHD, S. pyogenes may also
cause glomerulonephritis, another poststreptococcal
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tions, as well as uncomplicated pharyngites and
pyoderma.
The pathogenesis of RF and RHD depends on
several host factors that mediate a pathological
autoimmune response triggered by a defensive
response against S. pyogenes. Genetic predisposition
is one of the factors contributing to the development
of autoimmunity. Several genetic markers have been
studied; however the most consistent associations
were described for HLA class II genes. The HLA-
DR7 allele is the one most frequently associated with
the disease and seems to be related to the development
of multiple valvular lesions in RHD patients (see
review Guilherme et al. 2005). HLA class II molecules
are expressed on the surface of antigen-presenting
cells (APCs)—such as macrophages, dendritic cells,
and B cells—and, together with bound peptide
antigen, trigger the activation of T cells. The
interaction of HLA molecules, antigenic peptide and
T cell receptor (TCR) on the surface of T cells are
crucial for the activation of the immune response. In
autoimmune disease, HLA molecules combined with
certain peptides might cause inappropriate T cell
activation (Brand et al. 2005). In the case of RF,
during the throat infection period, several streptococ-
cal peptides are generated after processing by
macrophages and/or dendritic cells and, in association
with certain HLA class II molecules, activate CD4
þ
T cells that trigger humoral and cellular immune
responses against the bacteria that will later lead to
an autoimmune response (Figure 1). In RF/RHD,
the molecular mimicry mechanism mediates the
process whereby T cells recognize self-antigens with
some degree of homology to streptococcal antigens,
and provide help to autoreactive B cells. Both
antibodies and T cells play an important role in the
pathogenesis of RF/RHD. Several studies of the
humoral immune response allowed for the deﬁnition
of three major groups of crossreactivity, involving the
recognition of 1 alpha-helical coiled-coil molecules
such as myosin, tropomyosin and keratin; 2 myosin
and DNA; and 3 myosin and N-acetyl-glucosamine
(reviewed by Guilherme et al. 2006). The deposition
of these antibodies in the valve endothelium surface
triggers the inﬂammatory process, facilitating T cell
inﬁltration (Cunningham 2003). The presence of
CD4
þT cells in the heart lesions of RHD patients was
described in the 1980s (Raizada et al. 1983) and the
functional role of these cells was described 12 years
later, when molecular mimicry between the M protein
from beta-hemolytic streptococci and heart tissue
proteins was shown for the ﬁrst time through the
analysis of heart-tissue inﬁltrating T cell repertoires
leading to local tissue damage in RHD (Guilherme
et al. 1995).
Considering that RF/RHD are the prototypes for
post-infectious autoimmune disease, our greatest
challenge is to develop a vaccine to prevent S. pyogenes
infection and the diseases caused by these bacteria
without inducing autoimmune reactions.
Efforts to produce a vaccine against S. pyogenes date
fromseveraldecadesago,andarebasedontheuseofthe
M proteinasaninducerofprotection.Theﬁrstvaccine
Figure 1. Schematic representation of streptococcal throat infection and the activation of the immune response. In RF, during the throat
infection period, several streptococcal peptides are generated after processing by macrophages and/or dendritic cells and, in association with
certain HLA class II molecules, activate CD4
þT cells. The complex formed by HLA molecules, antigenic peptide and TCR is called a
“trimolecular complex” and is fundamental for triggering humoral and cellular immune responses to the bacteria that later may lead to an
autoimmune response in susceptible individuals.
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coccal M protein and evoked protective-type speciﬁc
immune responses (Polly et al. 1975; Beachey et al.
1979). Following the idea of a type-speciﬁc vaccine,
Dale and co-workers developed different vaccine
models using a multivalent type-speciﬁc recombinant
N-terminalMprotein,someofwhichareinclinicaltrial
(Kotloff et al. 2004; McNeil et al. 2005).
In parallel, other groups are using the conserved
C-region of the streptococcal M protein, which is
common to most strains (Fischetti et al. 1988), for
developing avaccine able to provide protection against
the majority of streptococcal strains. Fischetti and co-
workers deﬁned M protein C-terminal peptides
capable of inducing IgA antibodies and reported the
prevention of bacterial colonization in animal models
(Bessen and Fischetti 1988a,b). Following these
experiments, a live mucosal vaccine using Streptococcus
gordonii, acommensal organism, engineered to express
C-repeat M protein epitopes was developed and tested
in mice (Medaglini et al. 1995). The use of this
commensal vector as avaccine delivery vehicle is being
evaluated. Preliminary results show that the vector is
safe and well tolerated when tested by oral and nasal
routes in 150 healthy volunteers (Kotloff et al. 2005).
As mentioned before, RF/RHD incidence is very
high among Australian and New Zealand aborigines,
and, since there are particular streptococcal strains
involved with disease in these countries, a vaccine
model based on a combination of C- and N-terminal
peptides is being assayed (Brandt et al. 2000). The
most recent results from this group show that J14, a
29-mer peptide sequence which contains a conserved
epitope from the C-terminal repeat of the strepto-
coccal M protein, elicited protective opsonic anti-
bodies against several GAS isolates. In vivo challenge
experiments have also conﬁrmed the protective
efﬁcacy of immunization with J14 peptide in different
formulations (Vohra et al. 2005; Batzloff et al. 2005;
Olive et al. 2005).
Although these various vaccine models are currently
being developed, we have designed a new model of an
anti-streptococcalvaccinebasedonthenewconception
of the mechanisms of autoimmune reactions leading to
RF/RHD. Our studies have focused on the search for
protective Tand B cell epitopes by using a large panel
of human blood samples, tested against overlapping
peptides derived from the C-terminal portion of the
streptococcal M protein differing by only one amino
acidresidue.Ourapproachtakesintoconsiderationthe
afﬁnity of selected epitopes of binding to HLA class II
molecules and the ability of the peptide-HLA class II
complex to activate T cells via antigen TCR. T cell
activation will trigger B cell immune response inducing
the production of antibodies with protective potential.
This strategy has allowed us to deﬁne a common Tand
Bcellepitopethatisrecognizedbymostsubjectstested.
The efﬁcacy of the vaccine epitope for inducing both
humoral and cellular responses will be tested in
experimental animal models as a second step in the
validation of the epitope as a vaccine candidate.
Materials and methods
Patients
Blood samples from 296 patients including 129 with
RF (mean age 13.8 ^ 4.8) and 167 with RHD (91
patients with mean age 15.1 ^ 4.7 and 76 with mean
age 34.5 ^ 12.0) were collected. These patients were
followed for at least 5 years at the Heart Institute
(InCor), HC-FMUSP, in Sao Paulo, Brazil. All
patients were diagnosed according to the Jones criteria
(Dajani et al. 1995). Three hundred twenty-four
healthy subjects (mean age 37.7 ^ 9.3) with no
previous history of RF or recently documented
streptococcal throat infection were also included in
the study. All subjects were tested for the presence of
antibodies to streptolysin O (ASLO). Blood-sample
collection procedures were approved by the Heart
Institute Ethics Committee, and informed consent
was obtained from parents of patients under age 18
years participating in the study.
Peptides synthesis
Streptococcal M5 peptides were synthesized by solid
phase technology using 9-ﬂuorenylmethoxycarbonyl
(Fmoc) chemistry (Atherton and Sheppard 1989) on
an automated benchtop simultaneous multiple solid-
phase peptide synthesizer PSSM8 (Shimadzu, Japan)
checked by mass spectrometry (Ettan Maldi-TofPro,
Amershan-GE, Sweden), and puriﬁed using high-
pressure liquid chromatography (RP-HPLC,
Shimadzu, Japan). Seventy-nine overlapping C-term-
inal M5 20-mer peptides differing by only one amino
acid residue, were synthesized based on the previously
described streptococcal M5 protein sequence
(Figure 2) (Robinson et al. 1991). In a ﬁrst step, we
tested the 79 overlapping peptides by ELISA using
serum samples from 250 subjects, in order to
select those peptides most frequently recognized.
Thirty-eight overlapping peptides were selected and
then the number of serum samples was increased
(620 samples). The cellular response of 258 individu-
als was analyzed by proliferation assays to 38 selected
overlapping peptides.
ELISA
Ninety-six-well high binding plates (Immunoware,
Pierce Biotechnology, Rockford, USA) were pre-
viously coated with streptococcal M5 peptides
(25mg/ml) in 0.05M carbonate buffer pH 9.6 for 1h
at 378C. After washing with 0.1% PBS-Tween buffer
and blocking with 2% PBS-BSA buffer, serum
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and incubated for 18h at 48C. Bound antibodies
were detected using a secondary antibody (peroxidase
labeled rabbit anti-human IgG, Dako, Denmark)
incubated for 1h at 378C. After washing, OPD
(o-phenylediamine, Sigma-Aldrich Corporation, St
Louis, Missouri, USA) substrate was added for 30min
at 378C. The reaction was stopped with 2M H2SO4,
and M5 peptide-speciﬁc IgG was detected by reading
the OD at 490nm using an automated plate reader
(Bio-Tek Instruments, Inc.—mQuant, Winooski,
Vermont, USA).
Streptococcal adhesion and invasion assay
Cell cultures. HEp2 cells (human larynx carcinoma)
were cultured in Dulbecco’s Modiﬁed Eagle
Medium (D-MEM, Invitrogen, Carlsbad, CA, USA)
supplemented with L-glutamine 1mM, gentamicin
40mg/ml, cephalosporin 0.1ng/ml and 10% heat-
inactivated fetal calf serum (FCS), in a 5% CO2
incubator. After cell expansion, 3ml of trypsin-versene
solution (0.2% trypsin, 0.2% versene in PBS pH 7.4)
were added to remove the monolayer adherent cells.
Cells were then transferred to 24 wells plates with a
13mm glass slide.
S. pyogenes strains. S. pyogenes isolates were recovered
from random samples of oropharyngeal, tonsillar,
skin, or blood infections and other sources from
patients treated at the Clinical Hospital of the
University of Sao Paulo, and at the Laranjeiras
National Cardiology Institute, both in Brazil.
Identiﬁcation was based on characteristic hemolysis
in blood agar and sensitivity to bacitracin. After
emm gene ampliﬁcation and sequencing, M strains
were identiﬁed in a databank (BLAST 2 (National
Center for Biotechnology Information; available at
http://www.ncbi.nlm.nih.gov/BLAST and CDC,
Department of Health and Human Services, Centers
for Disease Control and Prevention, available at http://
www.cdc.gov/).
Adhesion/invasion assay. Semiconﬂuent monolayers of
HEp2 cells grown on glass cover slips incubated
without antibiotics in 24-well plates were infected with
streptococcus suspensions (7 £ 10
5 bacteria) for 2h
at 378C. Cells were then washed extensively with PBS
and ﬁxed with methanol for 20min and stained with
Giemsa for microscopy analysis. For the adherence
and invasion assay infected cells were treated with
trypsin-versene for 3–4min at 378C and lysed by
addition of 0.025% Triton-X100. Cell lysates were
diluted in phosphate buffered saline (PBS) and plated
on blood agar for the quantiﬁcation of the number of
viable bacteria measured as Colony Forming Units
(CFU). The ability to inhibit adhesion/invasion was
assayed with a pool of diluted sera (1:30) from healthy
subjects selected based on their humoral responses to
C-terminal streptococcal M protein peptides. Sera
were incubated with bacterial cells in suspension for
1h at 378C and then incubated with HEp2 cells as
described above. The percentage of inhibition was
calculated based on the numbers of streptococci CFU
before and after sera treatment.
Proliferation assay. Proliferation assays were performed
in 96-well plates by incubating 10
5 PBMC separated
by density gradient centrifugation (d ¼ 1078g/ml)
with 10mg/ml ofM protein derived-peptides for 5 days
at 378C in a humidiﬁed 5% CO2 incubator. Negative
controls were PBMC and medium in the absence of
peptides and positive controls were PBMC stimulated
with PHA-P (2.5mg/ml, Sigma-Aldrich Corporation,
St Louis, Missouri, USA). Antigens were tested
in triplicate and pulse-labeled with 0.5mCi/well of
tritiated thymidine (Amersham Pharmacia, England,
Figure 2. M protein C-terminal overlapping peptides. A region of 99 amino acid residues from the C-terminal portion of the M5 protein
(residues 253–350) (Robinson et al. 1991) was covered by 79 overlapping 20-mer peptides differing by one amino acid residue.
L. Guilherme et al. 128UK) in the ﬁnal 18h of culture. Cells were harvested
and analysed using a beta counter (Beta plate 1205-
LKB). Proliferative response was considered as
positive when the stimulation index (SI) was $2.0.
HLA typing. Hundred and ninety seven subjects (106
RF patients and 91 healthy controls) were typed for
HLA-DRB1, DRB3, DRB4, DRB5 and DQB1 by
PCR reactions using a commercial kit (micro SSPe
DNA,One Lambda, Ca, USA), following the
manufacture instructions.
Statistical analysis. The cut-off for humoral responses
tested by ELISA was established based on the OD
distribution of sera from healthy individuals and RF
patients, analysed using the box-plot method and the
Kruskal-Wallis Test (Rosner 1986) and deﬁned as the
median of OD values of each peptide tested.
Results
Deﬁnition of a B cell epitope in the C-terminal region of M
protein
Aiming to ﬁnd a common streptococcal epitope able
to induce the production of antibodies in healthy
individuals as well as in RF patients, we evaluated the
IgG response of 250 serum samples to 79 overlapping
C-terminal streptococcal M protein peptides
(Figure 2). Our results showed two regions of
reactivity in the sequence analyzed, one region
composed of 38 overlapping peptides (residues 253–
317), recognized by at least 50% of subjects tested,
and another region (residues 318–350), recognized by
a few subjects (data not shown). After this initial
screening, we increased the number of samples to 620
(324 from healthy individuals and 296 from RF
patients), which were tested against the 38 selected
peptides.Eleven overlapping peptideswere recognized
by more than 75% of both RF patients and healthy
subjects (Table I), which allowed us to deﬁne a 25-
residue B cell epitope (Table IV). Interestingly, when
we aligned the amino acid residues of the B cell
epitope, we observed a common core of 11 amino acid
residues (LRRDLDASREA).
Sera reactive to the B cell epitope inhibited adhesion and
invasion of S. pyogenes in vitro
We tested the ability of two pools of sera from healthy
individuals with positive and negative anti-streptoly-
sin O (ASLO), both reactive to the selected B cell
epitope, to inhibit cellular adhesion and invasion
of HEp2 cells by several strains of S. pyogenes
(M1, M5, M6, M71, M87 and M22). We observed
a high percentage of inhibition of adhesion/invasion
of strains M5 and M6 (99%), M44/61 (98%), M87
(97%), M1 (90%), M71 and M22 (70%) (Table II),
in both pools of sera.
Table I. Humoral reactivity against streptococcal M protein C-terminal peptides.
Reactivity (%)
Identiﬁcation M protein C-terminal peptides amino acid residues RF n ¼ 296 HC n ¼ 323
PepVac10
253SEASRKGLRRDLDASREAKK
272 85.5 92.0
PepVac11
254EASRKGLRRDLDASREAKKQ
273 90.2 90.7
PepVac12
255ASRKGLRRDLDASREAKKQL
274 83.8 84.8
PepVac49
291SRKGLRRDLDASREAKKQVEKK
310 84.1 78.6
PepVac50
292RKGLRRDLDASREAKKQVEK
311 91.9 87.6
PepVac51
293KGLRRDLDASREAKKQVEKA
312 87.5 88.2
PepVac18
261RRDLDASREAKKQLEAEQQK
280 83.1 77.4
PepVac38
280KLEEQNKISEASRKGLRRDL
299 76.7 81.1
PepVac42
284QNKISEASRKGLRRDLDASR
303 81.1 80.8
PepVac43
285NKISEASRKGLRRDLDASRE
304 75.3 80.2
PepVac45
287ISEASRKGLRRDLDASREAK
306 76.7 80.8
RF: RF patients; HC: healthy controls. Peptides selected with more than 75% of recognition in all tested groups (healthy individuals and RF
patients). Superscript numbers indicate the amino acid location in the all streptococcal M protein. A common amino acid sequence between
all peptides is underlined and bold typed.
Table II. S. pyogenes adhesion/invasion inhibition assay induced by
human sera.
S. pyogenes strains* Adhesion/invasion inhibition (%)
M5 99.0
M6 99.0
M44/61 98.0
M87 97.0
M1 90.0
M71 70.0
M22 70.0
*S. pyogenes strains were isolated from tonsils, throat or skin human
samples (Clinical Hospital, School of Medicine, University of Sa ˜o
Paulo, Sa ˜o Paulo and Laranjeiras Cardiology Institute, Rio de
Janeiro, Brazil) and identiﬁed by sequencing and alignment with
streptococcal strains previously described in data base (CDC,
Bioedit and EMBL gene bank). Sera thatinhibited the invasion were
selected from healthy individuals based on their antibody reactivity
against streptococcal C-terminal peptides (Table I).
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protein
We evaluated the cellular immune response of 258
individuals to the same 38 overlapping C-terminal M
protein peptides analysed in the humoral assays.
Based on the reactivity to 12 overlapping peptides
(Table III), we also deﬁned a T cell epitope composed
of 22 amino acid residues (Table IV). When we
aligned the overlapping peptides we found a common
core composed of 11 amino acid residues (KGLRR-
DLDASR).
It is interesting to note that, although located in
different regions of the C-terminal portion, both Tand
B cell epitopes showed an identical core of 16 amino
acidresidues—KGLRRDLDASREAKKQ(TableIV).
Once we could deﬁne both T and B epitopes we
constructed an entire peptide including both regions
to be tested as a vaccine candidate in animal models
(ongoing experiments). The identiﬁed peptides
sequences were deposited at the Brazilian Patent
Ofﬁce, INPI020050020064.
T cell epitope recognition is not HLA class II restricted
We performed HLA-DR and DQ typing of 197
individuals (106 RF patients and 91 healthy controls)
previously tested for T cell immune response. We
observed that the recognition of selected peptides
(Table III) was not restricted to any speciﬁc HLA-DR
or DQ antigens (data not shown).
Discussion
The development of a protective immune response to
prevent group A streptococci infections and RF/RHD
still remains a question that requires a deep knowledge
about the mechanism leading to pathological auto-
immune reactions and how a vaccine could act to
protect and avoid such effects. Nowadays we know
that both B and T immune responses are involved in
the M protein and human tissue proteins through
crossreactive reactions. There are evidences that the
pathogenesis of rheumatic carditis is mediated by
heart tissue crossreactive antibodies that cause an
inﬂammation into the valve endothelium that facili-
tates T cells inﬁltration (Cunningham 2003). Heart-
inﬁltrating cells in both myocardium and valves
produce inﬂammatory cytokines that enhance the
autoimmune reactions. Additionally, the scarce
numbers of cells producing the regulatory cytokine
IL-4 in the valves are probably responsible for the
progression and maintenance of chronic valve lesions
(Guilherme et al. 2004). These heart-inﬁltrating T
cells recognize peptides from both N-terminal region
of M protein and heart-tissue derived proteins such as
myosin and vimentin through molecular mimicry
(Guilherme et al. 1995, 2001; Fae ´ et al. 2006).
In the last 20 years several researchers have been
strivingtodevelopasafeandefﬁcaciousvaccineagainst
groupAstreptococci(Bisnoetal.2005).Asmentioned
before, the challenge to produce such vaccine is to
induce protection against S. pyogenes without develop-
ing autoimmune reactions that could trigger RF.
Antibodies directed against M protein could trigger
both autoimmunity and protection (Cunningham
2000 review). Vaccine strategies targeting N-terminal
Table III. Cellular reactivity against streptococcal M protein C-terminal peptides.
Reactivity (%)
Identiﬁcation M protein C-terminal peptides amino acid residues RF n ¼ 133 HC n ¼ 125
PepVac44
286KISEASRKGLRRDLDASREA
305 26.2 26.5
PepVac11
254EASRKGLRRDLDASREAKKQ
273 18.0 4.0
PepVac48
290ASRKGLRRDLDASREAKKQV
309 27.4 19.6
PepVac13
256SRKGLRRDLDASREAKKQLE
275 14.8 16.0
PepVac14
257RKGLRRDLDASREAKKQLEA
276 19.0 17.0
PepVac50
292RKGLRRDLDASREAKKQVEK
311 30.1 20.0
PepVac15
258KGLRRDLDASREAKKQLEAE
277 45.1 33.3
PepVac51
293KGLRRDLDASREAKKQVEKA
312 20.0 14.3
PepVac16
259GLRRDLDASREAKKQLEAEQQK
278 26.7 15.8
PepVac52
294GLRRDLDASREAKKQVEKAL
313 15.2 12.0
PepVac17
260LRRDLDASREAKKQLEAEQQ
279 21.6 14.3
PepVac53
295LRRDLDASREAKKQVEKALE
313 33.0 18.4
RF: RF patients; HC: healthy controls. Peptides selected with more than 10% of recognition in at least one of the tested groups (healthy
individuals and RF patients). Superscript numbers indicate the amino acid location in the all streptococcal M protein. A common amino acid
sequence between all peptides is underlined and bold typed.
Table IV. Alignmentof Tand B epitopesanddeﬁnitionof common
amino acid residues.
Epitopes Amino acid sequence
T cell KGLRRDLDASREAKKQLEAEQQ
B cell EASRKGLRRDLDASREAKKQVEKA
Underlined—the 16 amino acid residues common to both Tand B
epitopes.
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based on C-terminal region evoke broad serotype
protective antibodies.
So far there is no available vaccine, however two
phase I clinical trials are in progress and both are
based on the N-terminal region. One of these studies
evaluated the safety and immunogenicity of a
recombinantgroupAstreptococcalvaccinecontaining
N-terminalMproteinfragmentsfromserotypes1,3,5,
6, 19 and 24 and was tested in 28 healthy adult
volunteers(Kotloffetal.2004).Thefollow-upshowed
that the vaccine was well tolerated and evoked type-
speciﬁc opsonic antibodies against multiple serotypes
of group A streptococcus without eliciting antibodies
that cross-react with host tissues. Lately, a 26-valent
vaccine has been constructed that includes 80–90% of
serotypes that cause invasive infections or pharyngitis
in North America (Shulman et al. 2004). This vaccine
includesrecombinantproteinsthatcontainN-terminal
peptides from streptococcal protective antigen and M
proteins of 26 common pharyngitis, invasive, and/or
rheumatogenic serotypes and was tested in 30 healthy
adult volunteers (McNeil et al. 2005). However, it is
important to consider that the vaccine coverage may
not be the same in other continents, mainly in
developing countries where there is little information
regarding the distribution of M serotypes. Those
results have shown that an intramuscular dose of the
vaccine did not present evidence of rheumatogenicity
or nephritogenicity, and did not induce the production
of human tissue-reactive antibodies.
The model we propose here focused on the C-
terminal portion of M protein and is similar to other
groups (Brandt et al. 2000; Medaglini et al. 2005).
Differently from previously proposed models, our
approach searchs for a protective B and T cell epitopes
using a large panel of human samples. This strategy
allowed us to construct a candidate vaccine segment
composed by both Tand B epitopes with 16 identical
amino acids. The advantage of such construction is
the possibility to induce both T and B memory cells
that will probably elicit a stronger protective immune
response. In addition, the selected epitopes apparently
were able to bind to any HLA class II molecules and
activated T cells without HLA class II restriction as
measured by proliferation assays.
A similar construction was done by Good’s group in
Austra ´lia. They identiﬁed a region on the C-terminal
portion of M protein from prevalent strains of an
Aborigenal endemic area ﬁrst named P145
(Pruksakorn et al. 1994; Brandt et al. 2000) that
resemblestheBcellepitopeidentiﬁedinourstudyalong
withtheBrazilianpopulation.Thesamegroupproposed
anewvaccinesegmentcalledJ14bymodifyingtheirﬁrst
construction(P145)duetotheobservedcrossreactions
with myosin and keratin (Hayman et al. 1997).
In order to analyse whether the selected vaccine
epitope may induce any kind of crossreactivity with
heart tissue proteins we are testing the reactivity of the
selected peptides with human heart- inﬁltrating T cell
lines (HIL) obtained from RHD patients by prolifer-
ation assay and cytokine production. Our preliminary
results did not show crossreactivity (ongoing exper-
iments) indicating that the selected region could be a
good candidate vaccine. The use of HIL from RHD
patients is unique and reliable to control potential
pathological autoimmune reactions due to the vaccine
agent. Additionally, the vaccine epitope is being tested
in animal models.
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